long-term effects of glp-1 receptor agonists The cardiovascular beyond obesity and type 2 diabetes: An anti-atherosclerotic action GLP-1 receptor agonists show promise

Exendin-4, a glucagon-like peptide 1 receptor agonist, protects against amyloid-beta peptide-induced impairment of spatial learning and memory in rats

Similarly, GLP-1RA have shown to have a neuroprotective effect including delay in Alzheimers and Parkinsons disease onset as well progressions (118)

By weeks two and three, GIP receptor effects become more pronounced

GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials

Older adults are more likely to use them for medical reasons, and younger adults are more likely to take them for weight loss

In trials, exenatide improved post-meal glucose spikes (due to its gastric slowing effect and insulin boost after meals) and also moderately lowered fasting glucose